» Articles » PMID: 12421930

Expression of Programmed Death 1 Ligands by Murine T Cells and APC

Overview
Journal J Immunol
Date 2002 Nov 8
PMID 12421930
Citations 448
Authors
Affiliations
Soon will be listed here.
Abstract

Programmed death 1 (PD-1) is a new member of the CD28/CTLA-4 family, which has been implicated in the maintenance of peripheral tolerance. Two ligands for PD-1, namely, B7-H1 (PD-L1) and B7-DC (PD-L2), have recently been identified as new members of the B7 family but their expression at the protein level remains largely unknown. To characterize the expression of B7-H1 and B7-DC, we newly generated an anti-mouse B7-H1 mAb (MIH6) and an anti-mouse B7-DC mAb (TY25). MIH6 and TY25 immunoprecipitated a single molecule of 43 and 42 kDa from the lysate of B7-H1 and B7-DC transfectants, respectively. Flow cytometric analysis revealed that B7-H1 was broadly expressed on the surface of mouse tumor cell lines while the expression of B7-DC was rather restricted. PD-1 was expressed on anti-CD3-stimulated T cells and anti-IgM plus anti-CD40-stimulated B cells at high levels but was undetectable on activated macrophages or DCs. B7-H1 was constitutively expressed on freshly isolated splenic T cells, B cells, macrophages, and dendritic cells (DCs), and up-regulated on T cells by anti-CD3 stimulation on macrophages by LPS, IFN-gamma, GM-CSF, or IL-4, and on DCs by IFN-gamma, GM-CSF, or IL-4. In contrast, B7-DC expression was only inducible on macrophages and DCs upon stimulation with IFN-gamma, GM-CSF, or IL-4. The inducible expression of PD-1 ligands on both T cells and APCs may suggest new paradigms of PD-1-mediated immune regulation.

Citing Articles

The mononuclear phagocyte system obscures the accurate diagnosis of infected joint replacements.

Manasherob R, Warren S, Arora P, Heo L, Haddock N, Koliesnik I J Transl Med. 2024; 22(1):1041.

PMID: 39563367 PMC: 11575056. DOI: 10.1186/s12967-024-05866-5.


Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations.

Aldoughaim M, Alsuhebany N, Alzahrani M, Alqahtani T, Alghamdi S, Badreldin H Clin Med Insights Oncol. 2024; 18:11795549241298541.

PMID: 39559827 PMC: 11571259. DOI: 10.1177/11795549241298541.


Toxicity in the era of immune checkpoint inhibitor therapy.

Keam S, Turner N, Kugeratski F, Rico R, Colunga-Minutti J, Poojary R Front Immunol. 2024; 15:1447021.

PMID: 39247203 PMC: 11377343. DOI: 10.3389/fimmu.2024.1447021.


Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma.

Kim J, Kim Y, Nam H, Kim C, Yoo J, Han J Oncol Lett. 2024; 28(2):388.

PMID: 38966587 PMC: 11223005. DOI: 10.3892/ol.2024.14521.


Is There an Immunohistochemical PD-L1 Cut-Off Point That Serves as a Prognostic Indicator for Large B-Cell Lymphomas?.

Cin S, Aki S, Elverdi T, Ozmen D, Salihoglu A Diagnostics (Basel). 2024; 14(11).

PMID: 38893691 PMC: 11172057. DOI: 10.3390/diagnostics14111167.